The nonsurgical management of early stage (T1/2 N0 M0) laryngeal cancer: A population analysis

被引:2
|
作者
Lee, Kevin C. [1 ]
Chuang, Sung-Kiang [2 ,3 ]
机构
[1] New York Presbyterian Columbia Univ, Irving Med Ctr, Div Oral & Maxillofacial Surg, New York, NY USA
[2] Univ Penn, Dept Oral & Maxillofacial Surg, Philadelphia, PA 19104 USA
[3] Brockton Oral & Maxillofacial Surg Inc, Dept Oral & Maxillofacial Surg, Good Samaritan Med Ctr, Brockton, MA USA
关键词
SQUAMOUS-CELL CARCINOMA; EARLY GLOTTIC CANCER; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; PROGNOSTIC-FACTORS; LOCAL-CONTROL; RADIOTHERAPY; PRESERVATION; CHEMOTHERAPY; SURGERY;
D O I
10.1016/j.oooo.2020.01.006
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background. The purpose of this study was to evaluate the patterns of care and survival in the nonsurgical management of early-stage (T1/2 N0 M0) laryngeal cancer. Study Design. This was a retrospective cohort study using data from the Surveillance, Epidemiology, and End Results (SEER) database during the period 2004 to 2015. Patients diagnosed with T1/2 N0 M0 laryngeal SCC definitively treated without surgery were included. Study predictors were age, gender, race, marital status, histologic grade, stage, and management strategy defined as radiotherapy (RT), chemotherapy, chemoradiotherapy (CRT), or no treatment. Study outcomes were overall survival (OS) and disease-specific survival (DSS). Results. In total, 3221 patients comprised the final sample. Over half of the lesions were stage I (63.8%); 74.0%, 24.8%, and 1.2% were located in the glottis, supraglottis, and subglottis, respectively. RT (77.6%) was the preferred nonsurgical treatment modality, followed by CRT (12.7%). A greater proportion of patients with stage II disease (25.1%) received CRT compared with those with stage I (5.6%). Similarly, patients receiving CRT were significantly younger and more likely to present with higher-grade lesions located in the supraglottis and subglottis. In the multivariate model, the risks of both disease-specific and overall death were increased by age, male gender, supraglottic and subglottic location, stage II disease, CRT, and no treatment. Conclusions. Definitive RT was the preferred treatment modality regardless of tumor characteristics. CRT was more often selectively reserved for younger patients with higher grade, stage II tumors located in the supraglottis and subglottis. This approach may be driven by the poorer rates of survival associated with these particular characteristics. CRT did not appear to improve survival in comparison with RT after controlling for subsite and disease severity; however, future clinical studies are required to validate this finding.
引用
收藏
页码:18 / 24
页数:7
相关论文
共 50 条
  • [41] Rectal cancers T2 N0 M0, rectal preservation: a new field for the clinical research
    Gerard, J. -P.
    Benezery, K.
    Ortholan, C.
    Follana, P.
    Francois, E.
    Hannoun-Levi, J. -M.
    Marcie, S.
    ONCOLOGIE, 2008, 10 (10) : 612 - 616
  • [42] Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1-2 N0 M0 renal cell carcinoma
    Marchioni, Michele
    Martel, Tristan
    Bandini, Marco
    Pompe, Raisa S.
    Tian, Zhe
    Kapoor, Anil
    Cindolo, Luca
    Autorino, Riccardo
    Briganti, Alberto
    Shariat, Shahrokh F.
    Schips, Luigi
    Karakiewicz, Pierre I.
    WORLD JOURNAL OF UROLOGY, 2017, 35 (12) : 1899 - 1905
  • [43] Three dimensional conformal radiotherapy in patients with T2a-b, N0, M0 prostatic carcinoma
    Kurtman C.
    Celebioǧlu B.
    Göǧüs O.
    Andrieu M.N.
    International Urology and Nephrology, 2000, 32 (2) : 275 - 278
  • [44] Risk Factors for Locoregional Recurrence After Mastectomy in Stage T1 N0 Breast Cancer
    Hastings, Joseph
    Iganej, Shawn
    Huang, Cynthia
    Huang, Ronald
    Slezak, Jeff
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (05): : 486 - 491
  • [45] Is local excision an appropriate treatment modality in patients presenting with early-stage (cT1 N0 M0) rectal adenocarcinoma?
    Roat-Shumway, Siena
    Tonelli, Celsa
    Singer, Marc
    Cohn, Tyler
    Luchette, Fred A.
    Abdelsattar, Zaid
    Baker, Marshall S.
    SURGERY, 2023, 173 (03) : 665 - 673
  • [46] HER2/NEU OVEREXPRESSION IN pT1a OR pT1b, N0, M0 BREAST CANCER
    Petroni, S.
    Asselti, M.
    Giotta, F.
    Quero, C.
    D'Amico, C.
    Marzano, A. L.
    Daprile, R.
    Salvatore, C.
    Colucci, G.
    Simone, G.
    CANCER TREATMENT REVIEWS, 2010, 36 : S103 - S103
  • [47] Effect of radioisotope sentinel node mapping in patients with cT1 N0 M0 lung cancer
    Sugi, K
    Kaneda, Y
    Sudoh, M
    Sakano, H
    Hamano, K
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 126 (02): : 568 - 573
  • [48] TREATMENT OF MODIFIED STAGE-II (T1 N1 M0, T2 N1 M0) NON-SMALL CELL BRONCHOGENIC-CARCINOMA - A COMBINED MODALITY APPROACH
    NEWMAN, SB
    DEMEESTER, TR
    GOLOMB, HM
    HOFFMAN, PC
    LITTLE, AG
    RAGHAVAN, V
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1983, 86 (02): : 180 - 185
  • [49] T1 N0 Triple Negative Breast Cancer: A Bad Actor
    Livingston, Robert
    BREAST JOURNAL, 2009, 15 (05): : 451 - 453
  • [50] Lobectomy versus limited resection in T1 N0 lung cancer
    Lederle, FA
    ANNALS OF THORACIC SURGERY, 1996, 62 (04): : 1249 - 1249